Aquestive Therapeutics, Inc.

AQST: Is Aquestive Therapeutics, Inc. Halal?

Aquestive Therapeutics, Inc.

NASDAQHealthcareUS

$3.93

-1.75%

Market Cap: 390.3M

Compliance Status

Halal

Screened on Aug 30, 2026 · AAOIFI Standard 21

A

Very Good

80Score

Is Aquestive Therapeutics, Inc. (AQST) halal? Halal. Based on AAOIFI screening, Aquestive Therapeutics, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 80/100 (Grade: A).

Quote this verdict

HalalScreener rates Aquestive Therapeutics, Inc. (AQST) Halal, 80/100, grade A under AAOIFI Standard 21, screened Aug 30, 2026. Source: https://halalscreener.app/en/stock/AQST

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

8.7% of 30.0% limit

What this means for you

You can own AQST

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened AQST's prohibited income, but the exact share you would need to purify is part of Pro.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 30, 2026

Compliance History

  1. Halalnow

    since Aug 2026

  2. Doubtful

    until the change above

  3. Not Halal

    until the change above

  4. Doubtful

    until the change above

  5. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR
Free · No credit card required

Track AQST and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. (AQST) halal to invest in?
Based on AAOIFI Standard 21 screening, Aquestive Therapeutics, Inc. (AQST) is rated Halal with a compliance grade of A (Very Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).
Why did Aquestive Therapeutics, Inc. get a A compliance rating?
Aquestive Therapeutics, Inc. (AQST) received a grade of A (Very Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 8.7% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Aquestive Therapeutics, Inc.'s Shariah verdict?
Aquestive Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Aquestive Therapeutics, Inc. re-screened for Shariah compliance?
Aquestive Therapeutics, Inc. (AQST) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 30, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.